Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936997 | 0.86 | ADORA3 (0.52) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL196069 | 0.85 | RAB9A (0.59) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL196452 | 0.82 | GRM4 (0.47) | NPC1RAB9AGRM4MAPTTP53 | |
| SCHEMBL196377 | 0.82 | GRM4 (0.49) | NPC1RAB9AGRM4MAPTTP53 | |
| SCHEMBL30637139 | 0.81 | GRM4 (0.51) | NPC1RAB9AGRM4MAPTTP53 | |
| SCHEMBL29501836 | 0.81 | GRM4 (0.51) | NPC1RAB9AGRM4MAPTTP53 | |
| SCHEMBL196780 | 0.81 | GRM4 (0.51) | NPC1RAB9AGRM4MAPTTP53 | |
| SCHEMBL6238037 | 0.81 | NPY5R (0.60) | NPC1RAB9AMAPTNPY5RMEN1 | |
| SCHEMBL1850007 | 0.77 | IGF1R (0.63) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL196310 | 0.77 | RXFP1 (0.47) | NPC1RAB9AGRM4MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323661-B1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIV LEIDEN (NL) | 2013-04-17 | — | — | EP | claimed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | claimed |
| US-9668959-B2 | A3 adenosine receptor ligands for modulation of pigmentation | ORADIN PHARMACEUTICAL LTD. (IL) | 2017-06-06 | — | — | US | disclosed |
| EP-2456419-B1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD (IL) | 2016-11-23 | — | — | EP | disclosed |
| US-20160136079-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2016-05-19 | — | — | US | disclosed |
| US-9199102-B2 | A3 adenosine receptor ligands for modulation of pigmentation | ORADIN PHARMACEUTICAL LTD. (IL) | 2015-12-01 | — | — | US | disclosed |
| EP-2323661-B1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIV LEIDEN (NL) | 2013-04-17 | — | — | EP | disclosed |
| US-20120134945-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2012-05-31 | — | — | US | disclosed |
| EP-2456419-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | Oradin Pharmaceutical Ltd. (IL) | 2012-05-30 | — | — | EP | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| EP-2323661-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | Universiteit Leiden (NL) | 2011-05-25 | — | — | EP | disclosed |
| WO-2011010306-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010020981-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020981-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | ADORA3, ADORA2A, ADORA1 | NPC1 2737/4885RAB9A 1121/4885GRM4 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.